 Nemaura Medical Inc. NASDAQ: NMRD Nemaura or the Company, a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor CGM, together with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, today announced the pricing of a best efforts public offering of an aggregate of up to 1,586,206 shares of its common stock and warrants to purchase up to an aggregate of 793,103 shares of its common stock. Each share of common stock and accompanying one-half of a warrant is being sold for a combined purchase price of 7.25, for a gross deal size of 11.5 million, not including any future proceeds from the exercise of the warrants and before deducting the placement agent fees and offering expenses. The offering is expected to close on or about July 30, 2020, subject to satisfaction of customary closing conditions. 